Dec 9 (Reuters) - AbbVie Inc (N:ABBV) ABBV.N :
* Abbvie's humira (adalimumab) receives health Canada approval for the
extension of the polyarticular juvenile idiopathic arthritis indication for
patients between 2 and 4 years
* Humira will now be available to patients age 2 to 17 years living with
polyarticular jia, with the dose based on patient body surface area
* Source text for Eikon ID:nCNWnV9dLa
* Further company coverage ABBV.N